期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 175, 期 21, 页码 4036-4046出版社
WILEY
DOI: 10.1111/bph.14337
关键词
-
资金
- National Health and Medical Research Council (NHMRC) of Australia [APP1084487]
- Australian Government Research Training Program Scholarship
- Australian Research Council Discovery Early Career Researcher Award [DE130100117]
Adenosine receptors are a family of GPCRs containing four subtypes (A(1), A(2A), A(2B) and A(3) receptors), all of which bind the ubiquitous nucleoside adenosine. These receptors play an important role in physiology and pathophysiology and therefore represent attractive drug targets for a range of conditions. The theoretical framework surrounding drug action at adenosine receptors now extends beyond the notion of prototypical agonism and antagonism to encompass more complex pharmacological concepts. New paradigms include allostery, in which ligands bind a topographically distinct receptor site from that of the endogenous agonist, homomeric or heteromeric interactions across receptor oligomers and biased agonism, that is, ligand-dependent differential intracellular signalling. This review provides a concise overview of allostery, oligomerization and biased agonism at adenosine receptors and outlines how these paradigms may enhance future drug discovery endeavours focussed on the development of novel therapeutic agents acting at adenosine receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据